Post by Deleted on Jan 8, 2018 13:51:58 GMT
3. Rexahn Pharmaceuticals Inc. (RNN)
This clinical stage biopharmaceutical company is developing novel targeted cancer therapeutics.
The Company has 3 compounds in clinical testing - RX-3117, Supinoxin, and Archexin.
-- RX-3117 is under a two stage phase IIa clinical trial in patients with relapsed or refractory pancreatic cancer. Initial data readout from Stage 2 of the study is due this quarter.
-- RX-3117 in combination with Abraxane is in a phase IIa clinical study in patients newly diagnosed with metastatic pancreatic cancer who have had no prior chemotherapy.
-- Supinoxin is currently being investigated in a two stage phase IIa clinical proof-of-concept study in patients with metastatic triple negative breast cancer. Interim data from stage 1 of the clinical trial is due this quarter (Q4, 2017).
-- Archexin is under a phase IIa clinical proof-of-concept trial in metastatic renal cell carcinoma. Initial data readout from this trial is due this quarter (Q4, 2017).
RNN closed Wednesday's trading at $2.19, unchanged from the previous day's close.
www.nasdaq.com/article/watch-these-6-biotech-stocks-20171228-00065
C L
This clinical stage biopharmaceutical company is developing novel targeted cancer therapeutics.
The Company has 3 compounds in clinical testing - RX-3117, Supinoxin, and Archexin.
-- RX-3117 is under a two stage phase IIa clinical trial in patients with relapsed or refractory pancreatic cancer. Initial data readout from Stage 2 of the study is due this quarter.
-- RX-3117 in combination with Abraxane is in a phase IIa clinical study in patients newly diagnosed with metastatic pancreatic cancer who have had no prior chemotherapy.
-- Supinoxin is currently being investigated in a two stage phase IIa clinical proof-of-concept study in patients with metastatic triple negative breast cancer. Interim data from stage 1 of the clinical trial is due this quarter (Q4, 2017).
-- Archexin is under a phase IIa clinical proof-of-concept trial in metastatic renal cell carcinoma. Initial data readout from this trial is due this quarter (Q4, 2017).
RNN closed Wednesday's trading at $2.19, unchanged from the previous day's close.
www.nasdaq.com/article/watch-these-6-biotech-stocks-20171228-00065
C L
